PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

UK firm starts research on skin patch for COVID vaccines

Innoture has received funding from the Welsh Government to start proof-of-concept research into the use of its next-generation microneedle skin patch for the self-administration of COVID-19 and other vaccines.

Innoture has been awarded a grant of almost £200,000 from the Welsh Government via SMARTCymru 2014-2020 European Regional Development Fund West Wales and the Valleys to fund a research project entitled ‘Self-Administration of SARS-CoV-2 Vaccine via Microlithographic 3D printed Microstructure Patches’.

The group is now testing the patch’s ability to deliver a vaccine dose via the skin at its laboratories in the Institute of Life Science (ILS2) at Swansea University in Wales.

Dr Michael Graz, chief scientific officer of Innoture, said: “In the wake of the coronavirus pandemic, vaccine developers and manufacturers face a major challenge to rapidly develop and upscale their vaccination programmes as the demand for needles, glass vials plus other treatment delivery supplies, increases. Therefore, it is vital that alternative delivery options are considered by the UK – and international – health community.”

He added: “Our transdermal delivery system has the potential to improve patient experience and significantly reduce the burden on the NHS and other healthcare systems.

“The patch is painless and minimally invasive for patients to self-administer. At a time when self-isolation is necessary, the patch can be applied with ease in the home under guidance from a healthcare professional, reducing the need for people to attend a clinic. In addition, for healthcare professionals, it shortens consultation or appointment times and potentially removes the need for cold-chain storage.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026